Sirona Biochem (Seite 3098)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 30.04.24 15:18:17 von
neuester Beitrag 30.04.24 15:18:17 von
Beiträge: 31.028
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 34
Gesamt: 5.401.952
Gesamt: 5.401.952
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R · Symbol: ZSB
0,0435
EUR
+3,57 %
+0,0015 EUR
Letzter Kurs 03.05.24 Tradegate
Neuigkeiten
08.04.24 · globenewswire  |
05.04.24 · globenewswire |
28.03.24 · globenewswire |
13.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 38,27 | +28,16 | |
| 8,0780 | +27,90 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 3,6100 | +17,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 45.541.933 von Jon_Schnee am 30.09.13 18:42:29Wie schon erwähnt waren die Erwartungen hoch für den Skin-Whitening Deal. Viele erwarten einen grossen Namen wie L'Oreal etc... Nun ist es eine kleine Cosmetic Firma, die von einem mittelgrossen Pharmakonzern bald geschluckt wird. Na ja...
Antwort auf Beitrag Nr.: 45.541.909 von Jon_Schnee am 30.09.13 18:40:22Valeant claims victory in bidding war for Obagi Add to ...
Valeant Pharmaceuticals International Inc.’s apparent victory in the bidding war for skin-care company Obagi Medical Products Inc. should strengthen its presence in the dermatology segment and open the door to further geographical expansion.
Montreal-based Valeant sweetened its offer for California-based Obagi Medical Products Inc. to $24 (U.S.) in cash per share from $$19.75 last week after its initial bid was trumped by an all-cash $22-per-share proposal from Merz Pharma Group
Merz said on Monday it’s withdrawing from the bidding war, saying it isn’t comfortable pursuing the acquisition at these levels.
“Merz is a disciplined buyer and at this level the economics of such a transaction do not meet our requirements,” chief executive officer Philip Burchard said in a news release.
Canaccord Genuity analyst Neil Maruoka says he’d be surprised to see another rival bid surface.
Obagi no doubt represented a choice opportunity for privately held German firm Merz to gain a foothold in the U.S. market, he said.
“But, with Valeant’s dominant position in dermatology and its integration capabilities and ability to drive synergies, there was probably a view that they didn’t have the same capacities to drive value,” he said.
If the deal goes through for Valeant, it will be a “nice tuck-in for them. This represents all the characteristics they look for in a dermatology acquisition and presents opportunities outside the U.S., like Asia,” said Mr. Maruoka.
Valeant, Canada’s largest publicly traded drug company, unveiled its $343.8-million offer for Obagi last month. At the initial price of $19.75 per share, the bid represented a 28-per-cent premium to Obagi’s closing price on Nasdaq on March 19.
At the revised $24-per-share price, the proposed transaction is valued at about $418-million.
Valeant said when it first announced its proposal that the merger would provide annual cost synergies of at least $40-million.
Formerly Biovail Corp., Valeant made more than a dozen acquisitions last year, including the $2.6-billion takeover of Medicis Pharmaceutical Corp. of Scottsdale, Ariz., a maker of skin-care products.
Obagi’s biggest revenue generators are its Nu Derm anti-aging and acne treatment products.
Based in Long Beach, Calif., Obagi posted revenue of $120-million last year.
Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
Valeant Pharmaceuticals International Inc.’s apparent victory in the bidding war for skin-care company Obagi Medical Products Inc. should strengthen its presence in the dermatology segment and open the door to further geographical expansion.
Montreal-based Valeant sweetened its offer for California-based Obagi Medical Products Inc. to $24 (U.S.) in cash per share from $$19.75 last week after its initial bid was trumped by an all-cash $22-per-share proposal from Merz Pharma Group
Merz said on Monday it’s withdrawing from the bidding war, saying it isn’t comfortable pursuing the acquisition at these levels.
“Merz is a disciplined buyer and at this level the economics of such a transaction do not meet our requirements,” chief executive officer Philip Burchard said in a news release.
Canaccord Genuity analyst Neil Maruoka says he’d be surprised to see another rival bid surface.
Obagi no doubt represented a choice opportunity for privately held German firm Merz to gain a foothold in the U.S. market, he said.
“But, with Valeant’s dominant position in dermatology and its integration capabilities and ability to drive synergies, there was probably a view that they didn’t have the same capacities to drive value,” he said.
If the deal goes through for Valeant, it will be a “nice tuck-in for them. This represents all the characteristics they look for in a dermatology acquisition and presents opportunities outside the U.S., like Asia,” said Mr. Maruoka.
Valeant, Canada’s largest publicly traded drug company, unveiled its $343.8-million offer for Obagi last month. At the initial price of $19.75 per share, the bid represented a 28-per-cent premium to Obagi’s closing price on Nasdaq on March 19.
At the revised $24-per-share price, the proposed transaction is valued at about $418-million.
Valeant said when it first announced its proposal that the merger would provide annual cost synergies of at least $40-million.
Formerly Biovail Corp., Valeant made more than a dozen acquisitions last year, including the $2.6-billion takeover of Medicis Pharmaceutical Corp. of Scottsdale, Ariz., a maker of skin-care products.
Obagi’s biggest revenue generators are its Nu Derm anti-aging and acne treatment products.
Based in Long Beach, Calif., Obagi posted revenue of $120-million last year.
Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
Antwort auf Beitrag Nr.: 45.541.125 von Jon_Schnee am 30.09.13 16:51:37Valeant Pharmaceuticals übernimmt Obagi Medical Products
http://www.valeant.com/
RE:Valeant claims victory in bidding war for Obagi Add to ...
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
http://www.valeant.com/
RE:Valeant claims victory in bidding war for Obagi Add to ...
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
Sirona Biochem Signs Letter of Intent with Obagi Medical Products
http://www.stockhouse.com/News/Press-Releases/2013/09/30/Sir…
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 30, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB) announced today the signing of a Letter of Intent whereby Sirona Biochem will provide a global exclusive license to Obagi Medical Products to commercialize the skin lightening compound TFC-849. In exchange for this license, Sirona Biochem will receive upfront and milestone payments as well as ongoing royalty payments for global product sales.
"We are thrilled to be partnering with Obagi Medical Products to commercialize our skin lightening technology into a global market projected to reach $19.8 billion by 2018", said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "Our goal is to grow this relationship, developing a pipeline of leading compounds for Obagi Medical Products for sale around the world".
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
About the Betaclear (Skin Lightening) Project
Sirona Biochem's French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and European Union are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.
Read more at http://www.stockhouse.com/News/Press-Releases/2013/09/30/Sir…
http://www.stockhouse.com/News/Press-Releases/2013/09/30/Sir…
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 30, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB) announced today the signing of a Letter of Intent whereby Sirona Biochem will provide a global exclusive license to Obagi Medical Products to commercialize the skin lightening compound TFC-849. In exchange for this license, Sirona Biochem will receive upfront and milestone payments as well as ongoing royalty payments for global product sales.
"We are thrilled to be partnering with Obagi Medical Products to commercialize our skin lightening technology into a global market projected to reach $19.8 billion by 2018", said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "Our goal is to grow this relationship, developing a pipeline of leading compounds for Obagi Medical Products for sale around the world".
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
About the Betaclear (Skin Lightening) Project
Sirona Biochem's French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and European Union are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.
Read more at http://www.stockhouse.com/News/Press-Releases/2013/09/30/Sir…
Antwort auf Beitrag Nr.: 45.537.375 von Jon_Schnee am 30.09.13 07:46:11Die einen wollen Braun werden und legen sich ins Solarium, die anderen Weiss uns Cremen. Wir Menschen sind schon komische Wesen 
Ist ausser mir hier noch jemand investiert?
Ist ausser mir hier noch jemand investiert?
Trading Spotlight
Link zu Sirona Biochem:
http://www.sironabiochem.com/products/skinlightening/
Skin-Whitening Industry
Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
TOKYO—Under the glare of the sun, 27-year-old Ria Ko holds a parasol, wears long gloves and applies a new layer of SPF 50 sunscreen every couple of hours. Her pale complexion is hard won—acquired through a decade of effort to stay clear of the sun—and each freckle that appears causes her a moment of distress.
From Tokyo to Mumbai to Shanghai, the skin-whitening industry is booming and projected to grow into a $20 billion business globally by 2018, according to Global Industry Analysts.
In Asia, a fair complexion is synonymous with beauty, higher social position and wealth. Companies are scrambling to develop the next hot product in a culture that for centuries has identified light skin as a status symbol—because it proved that a woman was exempt from field work.
But the industry has been shaken after Japan's second-biggest cosmetics company, Kanebo Cosmetics Inc. said last week that it has confirmed the appearance of white stains—some bigger than 2 inches in diameter—on the faces, necks, and hands of thousands of women who had used its skin-lightening products.
The reports emerged after the company earlier this month recalled millions of products containing its Rhododenol brightening ingredient.
Kanebo, a unit of Kao Corp., 4452.TO +2.12% said it has received reports of skin conditions from 6,800 women, of whom 2,250 reported either splotches on multiple parts of the body, clearly visible splotches on the face, or large splotches. More than a hundred reports of similar cases have come in from Taiwan, Kanebo said.
Some of the unevenness faded after the women stopped using the Kanebo products, according to doctors and company spokesman Shinji Yamada. Doctors also said use of steroid-containing creams has helped some women.
The blow to Kanebo's brand is likely to lower its sales in the fiscal second half by about 10%, some analysts said. Others, including Daiwa Securities analyst Katsuro Hirozumi, said that the impact could be bigger, if damage to the Kanebo brand is such that consumers stop using all Kanebo cosmetics.
"This will leave an impact on consumers' perceptions of safety in skin-lightener products," said Euromonitor International analyst Mariko Takemura. The brand that triggered the recall, Kanebo Blanchir, is a popular skin whitener, and all cosmetics makers will need to address those concerns, she said.
Possible causes raised by dermatologists include allergic reactions following prolonged use of the products and sun exposure, but Kanebo's Mr. Yamada said that it could be months before the company understands why Rhododenol—which it developed over eight years followed by a three-year trial on 1,000 women—could cause skin disorders.
The company, which has promised to cover all related medical bills in women who show symptoms and is preparing to pay compensation, has enlisted Japan's dermatologist association for help.
In Japan, Asia's biggest market for skin whiteners, the fascination with pale skin dates back to at least the sixth century. Bihaku—or "beautiful white" in Japanese—came back into vogue in the 1990s amid a flurry of development of anti-aging and whitening substances by cosmetics firms.
Some 20 substances deemed effective in skin brightening have been approved by the Japanese government since 1988.
In some cases, it is hard to avoid substances added to skin-care products to lighten skin tones. More than 41% of facial moisturizers sold in Japan last year contained skin lighteners, on a retail value basis, according to Euromonitor. Skin lighteners made up roughly 20% of all skin-care products sold, says market-research firm Fuji Keizai.
On July 4, Kanebo recalled 4.36 million items containing its patented Rhododenol, or 4HPB, a synthetic version of a compound found in the bark of white birch trees. The recall covered all 54 of the company's products containing the substance and extended to Taiwan, Hong Kong, South Korea, Thailand, Singapore, Malaysia, Indonesia, Myanmar, Vietnam, the Philippines and the U.K.
The Japanese government, which had approved the substance in 2008, is warning consumers to stay away from products with Rhododenol. The U.S. Food and Drug Administration has issued an advisory on the Kanebo brands that contain the substance.
While Japan spends the most money on whiter skin, making it the world's biggest market for skin lighteners on a revenue basis, China and India are catching up fast, and will drive the global market to grow by 13% a year, according to Global Industry Analysts. Already, China and India have outstripped Japan in the use of skin-lightener materials in terms of volume. China used 422.7 tons of skin-lightener materials in skin-care products in 2012, almost five times as much as it used five years ago, while India's consumption grew more than four times in the same period to 233.6 tons, according to Euromonitor. That compares with 199.9 tons of skin lighteners used in Japan, the market-research firm said.
Kanebo, which was betting on Rhododenol to drive growth in a saturated Japanese market, has kept a tight hold on the substance, and it said it hasn't licensed its use outside the Kanebo group.
Shotaro Nagai, a spokesman at Shiseido Co., 4911.TO +0.34% Japan's biggest cosmetics firm, said Shiseido's sales of skin lighteners have risen slightly since Kanebo announced its recall. He didn't know if the two events were related, he said.
The Indian market for skin-whitening products is likely to grow by more than 8% in two years to about $428 million in 2013, or about half of an estimated $855 million market for facial-care products, according to Mintel, a market-research firm. "Fairness" is synonymous with beauty in much of India. In the matrimonial sections of the Sunday papers, prospective spouses regularly advertise their "fairness."
The large number of consumer complaints about skin stains in the past few weeks suggests that the skin problems have been festering for some time before they came to light. The scandal also casts doubt on the thoroughness of product-safety tests for mass-market skin-care products—especially of those that promise dramatic results, such as lighter skin color.
But the obsession with white skin continues, and some industry watchers are skeptical that consumers will stop buying whitening products.
"Whiter skin just looks better on Japanese women, as it brings out the fineness in skin texture," said Tokyo resident Yasumi Kawami, 33, who uses lightening products from Guerlain, a brand owned by LVMH Moët Hennessy Louis Vuitton SA. "People are not going to stop using bihaku products."
http://www.sironabiochem.com/products/skinlightening/
Skin-Whitening Industry
Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
TOKYO—Under the glare of the sun, 27-year-old Ria Ko holds a parasol, wears long gloves and applies a new layer of SPF 50 sunscreen every couple of hours. Her pale complexion is hard won—acquired through a decade of effort to stay clear of the sun—and each freckle that appears causes her a moment of distress.
From Tokyo to Mumbai to Shanghai, the skin-whitening industry is booming and projected to grow into a $20 billion business globally by 2018, according to Global Industry Analysts.
In Asia, a fair complexion is synonymous with beauty, higher social position and wealth. Companies are scrambling to develop the next hot product in a culture that for centuries has identified light skin as a status symbol—because it proved that a woman was exempt from field work.
But the industry has been shaken after Japan's second-biggest cosmetics company, Kanebo Cosmetics Inc. said last week that it has confirmed the appearance of white stains—some bigger than 2 inches in diameter—on the faces, necks, and hands of thousands of women who had used its skin-lightening products.
The reports emerged after the company earlier this month recalled millions of products containing its Rhododenol brightening ingredient.
Kanebo, a unit of Kao Corp., 4452.TO +2.12% said it has received reports of skin conditions from 6,800 women, of whom 2,250 reported either splotches on multiple parts of the body, clearly visible splotches on the face, or large splotches. More than a hundred reports of similar cases have come in from Taiwan, Kanebo said.
Some of the unevenness faded after the women stopped using the Kanebo products, according to doctors and company spokesman Shinji Yamada. Doctors also said use of steroid-containing creams has helped some women.
The blow to Kanebo's brand is likely to lower its sales in the fiscal second half by about 10%, some analysts said. Others, including Daiwa Securities analyst Katsuro Hirozumi, said that the impact could be bigger, if damage to the Kanebo brand is such that consumers stop using all Kanebo cosmetics.
"This will leave an impact on consumers' perceptions of safety in skin-lightener products," said Euromonitor International analyst Mariko Takemura. The brand that triggered the recall, Kanebo Blanchir, is a popular skin whitener, and all cosmetics makers will need to address those concerns, she said.
Possible causes raised by dermatologists include allergic reactions following prolonged use of the products and sun exposure, but Kanebo's Mr. Yamada said that it could be months before the company understands why Rhododenol—which it developed over eight years followed by a three-year trial on 1,000 women—could cause skin disorders.
The company, which has promised to cover all related medical bills in women who show symptoms and is preparing to pay compensation, has enlisted Japan's dermatologist association for help.
In Japan, Asia's biggest market for skin whiteners, the fascination with pale skin dates back to at least the sixth century. Bihaku—or "beautiful white" in Japanese—came back into vogue in the 1990s amid a flurry of development of anti-aging and whitening substances by cosmetics firms.
Some 20 substances deemed effective in skin brightening have been approved by the Japanese government since 1988.
In some cases, it is hard to avoid substances added to skin-care products to lighten skin tones. More than 41% of facial moisturizers sold in Japan last year contained skin lighteners, on a retail value basis, according to Euromonitor. Skin lighteners made up roughly 20% of all skin-care products sold, says market-research firm Fuji Keizai.
On July 4, Kanebo recalled 4.36 million items containing its patented Rhododenol, or 4HPB, a synthetic version of a compound found in the bark of white birch trees. The recall covered all 54 of the company's products containing the substance and extended to Taiwan, Hong Kong, South Korea, Thailand, Singapore, Malaysia, Indonesia, Myanmar, Vietnam, the Philippines and the U.K.
The Japanese government, which had approved the substance in 2008, is warning consumers to stay away from products with Rhododenol. The U.S. Food and Drug Administration has issued an advisory on the Kanebo brands that contain the substance.
While Japan spends the most money on whiter skin, making it the world's biggest market for skin lighteners on a revenue basis, China and India are catching up fast, and will drive the global market to grow by 13% a year, according to Global Industry Analysts. Already, China and India have outstripped Japan in the use of skin-lightener materials in terms of volume. China used 422.7 tons of skin-lightener materials in skin-care products in 2012, almost five times as much as it used five years ago, while India's consumption grew more than four times in the same period to 233.6 tons, according to Euromonitor. That compares with 199.9 tons of skin lighteners used in Japan, the market-research firm said.
Kanebo, which was betting on Rhododenol to drive growth in a saturated Japanese market, has kept a tight hold on the substance, and it said it hasn't licensed its use outside the Kanebo group.
Shotaro Nagai, a spokesman at Shiseido Co., 4911.TO +0.34% Japan's biggest cosmetics firm, said Shiseido's sales of skin lighteners have risen slightly since Kanebo announced its recall. He didn't know if the two events were related, he said.
The Indian market for skin-whitening products is likely to grow by more than 8% in two years to about $428 million in 2013, or about half of an estimated $855 million market for facial-care products, according to Mintel, a market-research firm. "Fairness" is synonymous with beauty in much of India. In the matrimonial sections of the Sunday papers, prospective spouses regularly advertise their "fairness."
The large number of consumer complaints about skin stains in the past few weeks suggests that the skin problems have been festering for some time before they came to light. The scandal also casts doubt on the thoroughness of product-safety tests for mass-market skin-care products—especially of those that promise dramatic results, such as lighter skin color.
But the obsession with white skin continues, and some industry watchers are skeptical that consumers will stop buying whitening products.
"Whiter skin just looks better on Japanese women, as it brings out the fineness in skin texture," said Tokyo resident Yasumi Kawami, 33, who uses lightening products from Guerlain, a brand owned by LVMH Moët Hennessy Louis Vuitton SA. "People are not going to stop using bihaku products."
Mit Sirona Biochem 34% im Plus. Seis drum, Kurs läuft derzeit stark nach oben. Es scheint das viele bald gute News erwarten und vor der News drin sein wollen. Ich warte hier schon lange. Ausser ein paar nette LOI Verträge (das ist doch mal ein Anfang) ist nichts fix. Erwartungen sind recht hoch. Enttäuschungspotential auch.
Management: nicht nur labern, liefern!!!
http://www.stockhouse.com/companies/quote/v.sbm/sirona-bioch…
Management: nicht nur labern, liefern!!!
http://www.stockhouse.com/companies/quote/v.sbm/sirona-bioch…
Business growth: Growing without risking it all
http://www.biv.com/article/20130910/BIV0112/309109952/-1/BIV…
http://www.biv.com/article/20130910/BIV0112/309109952/-1/BIV…
Antwort auf Beitrag Nr.: 45.488.879 von Jon_Schnee am 20.09.13 14:55:17Sirona Biochem läuft... 0.18 CAD + 16% = neues 52 Wochen Hoch
http://www.stockhouse.com/Companies/Quote/v.sbm/sirona-bioch…
http://www.stockhouse.com/Companies/Quote/v.sbm/sirona-bioch…
Sirona Closes Oversubscribed Private Placement
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 19, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB), (the "Company") is pleased to announce that it has closed its private placement in the amount of 9,748,834 units at $0.12 per unit for total gross proceeds of $1,169,860. Each unit consists of one common share and one transferable share purchase warrant, each warrant exercisable into one additional common share of the Company for a period of two years from the date of issue at a price of $0.16 per share.
"This is a tremendous outcome for Sirona Biochem and demonstrates the ongoing support of our shareholders as we continue the development of our technology portfolio," said Chief Executive Officer Neil Belenkie. "This successful equity financing allows us to focus on monetization of our core assets while advancing the technology pipeline."
The Company would like to acknowledge the participation of the Bloom Burton Canadian Healthcare Fund LP in this financing.
The Company paid a total of $36,652.80 in cash and issued a total of 305,440 share purchase warrants to finders in connection with the placement. Each finder's warrant is exercisable into one common share of the Company for a period of two years at a price of $0.16 per share.
All securities issued under the placement are subject to statutory hold periods expiring on January 19, 2014.
Proceeds of the placement will be used for general working capital.
About Sirona Biochem Corp.
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 19, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB), (the "Company") is pleased to announce that it has closed its private placement in the amount of 9,748,834 units at $0.12 per unit for total gross proceeds of $1,169,860. Each unit consists of one common share and one transferable share purchase warrant, each warrant exercisable into one additional common share of the Company for a period of two years from the date of issue at a price of $0.16 per share.
"This is a tremendous outcome for Sirona Biochem and demonstrates the ongoing support of our shareholders as we continue the development of our technology portfolio," said Chief Executive Officer Neil Belenkie. "This successful equity financing allows us to focus on monetization of our core assets while advancing the technology pipeline."
The Company would like to acknowledge the participation of the Bloom Burton Canadian Healthcare Fund LP in this financing.
The Company paid a total of $36,652.80 in cash and issued a total of 305,440 share purchase warrants to finders in connection with the placement. Each finder's warrant is exercisable into one common share of the Company for a period of two years at a price of $0.16 per share.
All securities issued under the placement are subject to statutory hold periods expiring on January 19, 2014.
Proceeds of the placement will be used for general working capital.
About Sirona Biochem Corp.
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Durchsuchen
